Prostate specific antigen best practice statement: 2009 update

Journal of Urology

Volumn 189, Issue 1 SUPPL, 2013, Pages

  Greene, Kirsten L ^a   Albertsen, Peter C ^a   Babaian, Richard J ^a   Carter, H Ballentine ^a   Gann, Peter H ^a   Han, Misop ^a   Kuban, Deborah Ann ^a   Sartor, A Oliver ^a   Stanford, Janet L ^a   Zietman, Anthony ^a   Carroll, Peter ^a  

^a American Urological Association   (United States)

Author keywords

mass screening; neoplasm staging; prostate specific antigen; prostatic neoplasms; treatment outcome

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CLINICAL PRACTICE; COMORBIDITY; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; ETHNICITY; FAMILY HISTORY; GLEASON SCORE; HEALTH CARE PERSONNEL; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY;

EID: 84870893888     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.11.014     Document Type: Article

References (51)

1. F.H. Schroder, J. Hugosson, M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 11320
2. L.A. Ries, D. Melbert, M. Krapcho et al. SEER Cancer Statistics Review, 1975-2005 Bethesda: National Cancer Institute http://seer.cancer.gov/csr/1975- 2005/ Based on November 2007 SEER data submission posted to the SEER web site 2008
3. R. Etzioni, A. Tsodikov, A. Mariotto Quantifying the role of PSA screening in the US prostate cancer mortality decline Cancer Causes Control 19 2008 175
4. R. Etzioni, R. Gulati, S. Falcon Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach Med Decis Making 28 2003 323
5. A. Bill-Axelson, L. Holmberg, M. Ruutu Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 352 2005 1977
6. Y.N. Wong, N. Mitra, G. Hudes Survival associated with treatment vs. observation of localized prostate cancer in elderly men JAMA 296 2006 2683
7. G.L. Andriole, R.L. Grubb, S.S. Buys Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310
8. E.M. Messing, J. Manola, M. Sarosdy Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781
9. J.I. Epstein, P.C. Walsh, M. Carmichael Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368
10. L. Cheng, C.K. Poulos, C.X. Pan Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens J Urol 174 2005 898
11. C. Jeldres, N. Suardi, J. Walz Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men Eur Urol 54 2008 1306
12. A.V. D'Amico, M.H. Chen, K.A. Roehl Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy N Engl J Med 351 2004 125
13. C. Gosselaar, M.J. Roobol, S. Roemeling Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam Prostate 66 2006 625
14. I. Tzanakis, S. Kazoulis, N. Girousis Prostate-specific antigen in hemodialysis patients and the influence of dialysis in its levels Nephron 90 2002 230
15. P.R. Slev, S.L. La'ulu, W.L. Roberts Intermethod differences in results for total PSA, free PSA, and percentage of free PSA Am J Clin Pathol 129 2008 952
16. R.D. Etzioni, D.P. Ankerst, N.S. Weiss Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence J Natl Cancer Inst 99 2007 1510
17. I.M. Thompson, D.P. Ankerst, C. Chi Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower JAMA 294 2005 66
18. J.E. Oesterling, S.J. Jacobsen, C.G. Chute Serum prostate-specific antigen in a community-based population of healthy men Establishment of age-specific reference ranges JAMA 270 1993 860
19. H.B. Carter, J.D. Pearson, J. Metter Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease JAMA 267 1992 2215
20. J.W. Moul, L. Sun, J.M. Hotaling Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening J Urol 177 2007 499
21. H.B. Carter, L. Ferrucci, A. Kettermann Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability J Natl Cancer Inst 98 2006 1521
22. A.J. Vickers, C. Savage, M.F. O'Brien Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer J Clin Oncol 27 2009 398
23. A. Reed, D.P. Ankerst, B.H. Pollock Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer J Urol 178 2007 1929
24. S. Loeb, K.A. Roehl, W.J. Catalona Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age? BJU Int 101 2008 817
25. W.J. Catalona, A.W. Partin, K.M. Slawin Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic diseases JAMA 279 1998 1542
26. B. Djavan, M. Remzi, A.R. Zlotta Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial Urology 60 2002 4
27. I.M. Thompson, D.K. Pauler, P.J. Goodman Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter N Engl J Med 350 2004 2239
28. S. Loeb, K.A. Roehl, J.A. Antenor Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old Urology 67 2006 316
29. T.O. Morgan, S.J. Jacobsen, W.F. McCarthy Age-specific reference ranges for prostate-specific antigen in black men N Engl J Med 335 1996 304
30. G.L. Andriole, R.L. Grubb, S.S. Buys Further analyses from the REDUCE prostate cancer risk reduction trial J Urol 181 suppl 2009 555 abstract LBA1
31. I. Thompson, P. Goodman, C. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215
32. P.C. Albertsen, J.A. Hanley, G.H. Barrows Prostate cancer and the Will Rogers phenomenon J Natl Cancer Inst 97 2005 1248
33. K.S. Ross, H.A. Guess, H.B. Carter Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages Urology 66 2005 1038
34. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 149 2008 185
35. S. Loeb, C.M. Gonzalez, K.A. Roehl Pathological characteristics of prostate cancer detected through prostate specific antigen based screening J Urol 175 2006 902
36. K.A. Roehl, M. Han, C.G. Ramos Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results J Urol 172 2004 910
37. Z. Levran, J.A. Gonzalez, A.C. Diokno Are pelvic computed tomography, bone scan, and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol 75 1995 778
38. S.J. Freedland, L.A. Mangold, P.C. Walsh The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy J Urol 174 2005 1276
39. S. Abuzallouf, I. Dayes, H. Lukka Baseline staging of newly diagnosed prostate cancer: a summary of the literature J Urol 171 2004 2122
40. F.C. Burkhard, M. Schumacher, U.E. Studer The role of lymphadenectomy in prostate cancer Nat Clin Pract Urol 2 2005 336
41. U. Ganswindt, A. Stenzl, M. Bamberg Adjuvant radiotherapy for patients with locally advanced prostate cancer - a new standard? Eur Urol 54 2008 528
42. M.S. Cookson, G. Aus, A.L. Burnett Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes J Urol 177 2007 540
43. A.J. Stephenson, M.W. Kattan, J.A. Eastham Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition J Clin Oncol 24 2006 3973
44. M. Zelefsky, D.A. Kuban, L.B. Levy Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation Int J Radiat Oncol Biol Phys 67 2007 327
45. E.M. Horwitz, H.D. Thames, D.A. Kuban Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis J Urol 173 2005 797
46. D. Robinson, G. Sandblom, R. Johansson The Scandinavian Prostate Cancer Group PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer Urology 72 2008 903
47. A.J. Stewart, H.I. Scher, M.H. Chen Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure J Clin Oncol 23 2005 6556
48. B.J. Trock, M. Han, S.J. Freedland Prostate cancer-specific survival following salvage radiotherapy vs. observation in men with biochemical recurrence after radical prostatectomy JAMA 299 2008 2760
49. K.M. Sanderson, D.F. Penson, J. Cai Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer J Urol 176 2006 2025
50. S.J. Freedland, E.B. Humphreys, L.A. Mangold Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 2005 433
51. A.V. D'Amico, J.W. Moul, P.R. Carroll Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Natl Cancer Inst 95 2003 1376